Pfizer (PFE) EPS (Weighted Average and Diluted) (2009 - 2026)

Pfizer (PFE) has 18 years of EPS (Weighted Average and Diluted) data on file, last reported at $0.47 in Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.47, down 9.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.31 (down 29.57% YoY), and the FY2025 annual result was $1.36, down 3.55% from the prior year.
• EPS (Weighted Average and Diluted) grew to $0.47 in Q1 2026 per PFE's latest filing, from -$0.29 in the prior quarter.
• Over five years, EPS (Weighted Average and Diluted) peaked at $1.73 in Q3 2022 and troughed at -$0.59 in Q4 2023.
• A 5-year average of $0.54 and a median of $0.52 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
• The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) sank 127.81% in 2023, then surged 5000.0% in 2025.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.51 in 2022, then plunged by 139.07% to -$0.59 in 2023, then surged by 232.2% to $0.78 in 2024, then tumbled by 137.18% to -$0.29 in 2025, then surged by 262.07% to $0.47 in 2026.
• Business Quant data shows PFE's EPS (Weighted Average and Diluted) at $0.47 in Q1 2026, -$0.29 in Q4 2025, and $0.62 in Q3 2025.